Forest earnings drop on higher costs

Forest Laboratories ($FRX) posted a drop in fiscal second-quarter earnings on higher costs, but sales rose 9%, thanks to strong early sales of two new products. But revenue still depends heavily on two older products, Lexapro and Namenda, that are on the verge of losing patent protection, and analysts wonder whether Forest's new drugs are novel enough to capture sizable market share. Report | News

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.